Palvella Therapeutics, Inc. (PVLA) Q2 FY26 Earnings Call

95% of patients improved at week 24, and potential FDA approval remains on track for the first half of 2027.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length60 minutes
EPS$-1.52
EPS consensus$-1.16

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All PVLA earnings ยท Back to PVLA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.